Background: This meta-analysis evaluated the efficacy and toxicity of gefitinib with other
commonly used drugs in different treatment settings and epidermal growth factor receptor …

BACKGROUND: Gefitinib is an oral tyrosine kinase inhibitor against the epidermal growth
factor receptor (EGFR). It has been shown to be active in patients with advanced non-small …

This study aimed to perform a meta-analysis comparing the efficacy and safety of gefitinib in
combination with chemotherapy versus gefitinib alone in patients with advanced Non-Small …

Gefitinib is an orally bioavailable, EGF receptor tyrosine kinase inhibitor and was the first
targeted drug to be approved for non-small-cell lung cancer (NSCLC). Identification of …

Introduction: Gefitinib is an EGFR tyrosine kinase inhibitor (EGFR-TKI) that demonstrated
efficacy in patients with advanced non-small cell lung cancer (NSCLC) across therapy lines …

Background: The epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and
erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis …

To define the efficacy of gefitinib in chemotherapy-naive patients with advanced non-small
cell lung cancer, we carried out a meta-analysis of randomised controlled trials. Medline …

Background Gefitinib is widely used in patients with advanced non-small-cell lung cancer
(NSCLC), in whom chemotherapy had failed. Previous trials reported inconsistent findings …

Background Gefitinib is active in patients with pretreated non-small-cell lung cancer
(NSCLC). We evaluated the activity and toxicity of gefitinib first-line treatment in advanced …

OBJECTIVE: Gefitinib, a small molecule tyrosine kinase inhibitor, showed a substantial effect
as a salvage treatment for patients with advanced non-small cell lung cancer (NSCLC) who …